2022 PAR AGM, page-13

Monitoring retail level sentiment would not be a prudent use of capital.
Keep in mind that markets are moved by huge operators, and large institutions need retail hype to sell to after they've sucked up the supply, sent a market up and are ready to get out on a seemingly positive announcement - which they've been doing since June 2020 (and of note Nov 3rd 2021).

I bought into this years ago based on the advertising campaign (fund managers talking about special funds dedicated to PAR lol).
Bio specs are a rough game as an investment unless you're a highly educated medical professional with inside knowledge - or the operators that run these things up and move onto the next one.